Article Versions Notes

Firneisz G, Rosta K, Al-Aissa Z, Hadarits O, Harreiter J, Nádasdi Á, Bancher-Todesca D, Németh L, Igaz P, Rigó J Jr., et al. The MTNR1B rs10830963 Variant in Interaction with Pre-Pregnancy BMI is a Pharmacogenetic Marker for the Initiation of Antenatal Insulin Therapy in Gestational Diabetes Mellitus. International Journal of Molecular Sciences. 2018; 19(12):3734. https://doi.org/10.3390/ijms19123734

Firneisz, Gábor, Klara Rosta, Zahra Al-Aissa, Orsolya Hadarits, Jürgen Harreiter, Ákos Nádasdi, Dagmar Bancher-Todesca, László Németh, Péter Igaz, János Rigó, Jr., and et al. 2018. "The MTNR1B rs10830963 Variant in Interaction with Pre-Pregnancy BMI is a Pharmacogenetic Marker for the Initiation of Antenatal Insulin Therapy in Gestational Diabetes Mellitus" International Journal of Molecular Sciences 19, no. 12: 3734. https://doi.org/10.3390/ijms19123734

Firneisz, G., Rosta, K., Al-Aissa, Z., Hadarits, O., Harreiter, J., Nádasdi, Á., Bancher-Todesca, D., Németh, L., Igaz, P., Rigó, J., Jr., Sziller, I., Kautzky-Willer, A., & Somogyi, A. (2018). The MTNR1B rs10830963 Variant in Interaction with Pre-Pregnancy BMI is a Pharmacogenetic Marker for the Initiation of Antenatal Insulin Therapy in Gestational Diabetes Mellitus. International Journal of Molecular Sciences, 19(12), 3734. https://doi.org/10.3390/ijms19123734